Pfenex One Step Closer To Teriparatide As FDA Accepts NDA

Pfenex maintains it can introduce a follow-on version of Eli Lilly’s Forteo in the fourth quarter of this year, after receiving a target goal date of 7 October 2019 from the FDA.

SmilingWoman
Pfenex is hoping to launch its follow-on teriparatide product by the end of 2019 • Source: Shutterstock

The US Food and Drug Administration (FDA) has set a target goal date of 7 October 2019 for Pfenex’ PF708 proposed follow-on version of Eli Lilly’s Forteo (teriparatide) after accepting the company’s 505(b)(2) new drug application (NDA).

With this step, chief executive officer Eef Schimmelpennink observed, “We believe PF708 remains on track to enter the US market...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Value Added Medicines

  • Neuraxpharm Enters Japanese Market 1

     
    • By 

    Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

  • Hyloris Sets Out Plans To Expand Its Pipeline

     
    • By 

    After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

  • Awards Offers Two Weeks Of Online Networking

     
    • By 

    From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

  • Hyloris And Purna Strike Value-Added Development Deal

     
    • By 

    Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.